Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
about
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancerRamucirumab in metastatic colorectal cancer: evidence to date and place in therapyInhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancerscVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis.Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapiesNoninvasive characterization of pancreatic tumor mouse models using magnetic resonance imagingThe VEGF family in cancer and antibody-based strategies for their inhibition.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.Clinical advances in the development of novel VEGFR2 inhibitors.Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumabDocetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel futurePivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Novel targeted agents in the treatment of lung cancer.Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancerRandomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activityTherapeutic targeting of receptor tyrosine kinases in lung cancer.Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasisAnti-angiogenic treatment of gastrointestinal malignancies.Hypoxia and angiogenesis in pancreatic cancer.Overexpression of VEGF121, but not VEGF165 or FGF-1, improves oxygenation in MCF-7 breast tumours.The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic CancerArsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-GliStem cell-based therapy in gastroenterology and hepatology.Regulation of blood vessel versus lymphatic vessel growth in the corneaSmall molecule tyrosine kinase inhibitors in pancreatic cancer.VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.In vitro models of pancreatic cancer for translational oncology research.Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.Defining new paradigms for the treatment of pancreatic cancer.Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies.Vandetanib for the treatment of thyroid cancer: an update.Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?
P2860
Q24801511-10F48EFD-F811-47B1-8418-3F0486A975FDQ26745418-D714E990-8686-4AA4-949F-CBE8A53E04B8Q29547558-260A741D-D87B-4846-BC88-B84A53CB0FC1Q30425448-787C47CD-C7E7-4190-B420-5A712F674A3CQ33417105-464957DD-359F-4607-9721-1DE1EB72616FQ33563635-3A412494-D2EC-404F-8EE1-27E7EADE23F2Q33679670-965E0932-C5E2-4CB1-9166-A708A452AAD3Q33733437-D74DD6FB-5E5C-4D35-8A22-D0BEC29CC1D6Q33824587-334D49E2-D0A1-4A53-9A4B-DC3DDA5EDC78Q34049260-A4D9E36D-1C80-49A4-98BD-519D7BE6D85AQ34098565-5D875888-4A1E-4E9A-8580-3A4CDAEE525CQ34348691-046ED0A5-5AC1-4F30-9967-ED9FA375CE5AQ34658366-5888A39C-3D78-4B9E-8BDE-B7D8DDFF063AQ34694813-22EA2E05-89F0-482A-99C6-E088E8FCA496Q34835853-159B893D-8EF8-4EEB-B8DA-12394D318BB0Q35640101-D37B9FCE-0A04-4FF2-872C-884F29A645F5Q35782469-F4CD2402-B9D8-4C9E-8578-D49E221BE61BQ35790783-C14DCEA1-E7E7-4E20-8CE3-E4E8E0CB0F2DQ35791879-80862480-7CD2-4779-A1C0-75FD1EA10300Q35904219-D36CBB39-998E-4747-B68E-826A62685876Q36041152-4E46B7CF-B392-4817-B973-414D53459157Q36146888-1C621794-9C66-4812-8694-9763555AF350Q36158717-C1A1D777-A1D5-4746-A750-2227332F646CQ36322698-6822F72C-6F28-4065-B07F-B9F17950A6D2Q36353516-19551541-8CC9-4F62-B0FD-728BBA5E8924Q36572752-A5041D04-50B4-418D-BCED-AA4E845F19F2Q36694450-1918F66C-913D-4455-BCD7-645B8E94AF4EQ36761584-5F70C531-A932-484E-82C4-938F6BA53BAAQ36791698-2539138D-3B19-4F92-AFC2-353F2D4A746CQ37120649-D410C55E-94EA-4FE8-8877-F0E8C7275026Q37157674-FC62C570-94EB-44F3-AD27-A5A6DF8EC31DQ37242034-82C96267-4D19-4F3F-8139-B25FAF85F9CBQ37307832-8B063A67-F86B-4663-9134-234197CEB0AFQ37345045-3949E603-A2CC-4FE6-BB49-3D61A7A8AA9AQ37384842-14F71093-660B-4F53-BA97-508B16716AFBQ37413669-E034F3D7-30EA-4F87-9B10-39BDC7F8DA5EQ37860976-E26387C0-27E5-4F82-B2F0-7BC37C1B137DQ38065976-4C2C8405-C8CF-4EDE-A109-A87BA42FFBFDQ38185691-D6321189-CF08-4BB3-8E28-318C822558C2Q39022032-3FCEF3EF-CB24-4401-BE3F-1C3A52E5E285
P2860
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effect of the vascular endothe ...... g orthotopically in nude mice.
@en
Effect of the vascular endothe ...... g orthotopically in nude mice.
@nl
type
label
Effect of the vascular endothe ...... g orthotopically in nude mice.
@en
Effect of the vascular endothe ...... g orthotopically in nude mice.
@nl
prefLabel
Effect of the vascular endothe ...... g orthotopically in nude mice.
@en
Effect of the vascular endothe ...... g orthotopically in nude mice.
@nl
P2093
P2860
P356
P1476
Effect of the vascular endothe ...... g orthotopically in nude mice.
@en
P2093
Carmen C Solorzano
Charles Portera
Christiane J Bruns
Daniel J Hicklin
Lee M Ellis
Marissa Shrader
Matthew T Harbison
Robert Radinsky
P2860
P304
P356
10.1002/IJC.10681
P577
2002-11-01T00:00:00Z